 Panitumumab is a fully human anti-epidermal factor receptor (EGFR) monoclonal antibody (mAb) that has been approved by the United States Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancers that express the EGFR and are unresponsive to chemotherapy (1). This mAb has a very high affinity for the extracellular domain III of the EGFR. The general characteristics of panitumumab have been described by Argiles et al. (2), and its mode of action has been illustrated by Dubois and Cohen (1). The fully human mAb has been reported to be well tolerated by individuals, slows disease progression, and improves the progression-free survival of patients (3). Therefore, [